|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61P 5/24 | (2006.01) |
| (11) | Number of the document | 3045182 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16154418.4 |
| Date of filing the European patent application | 2006-11-02 | |
| (97) | Date of publication of the European application | 2016-07-20 |
| (45) | Date of publication and mention of the grant of the patent | 2018-03-07 |
| (46) | Date of publication of the claims translation | 2018-05-10 |
| (30) | Number | Date | Country code |
| 736623 P | 2005-11-14 | US |
| (72) |
ZELLER, Joerg, US
POULSEN, Kristian Todd, US
ABDICHE, Yasmina Noubia, US
PONS, Jaume, US
ROSENTHAL, Arnon, US
COLLIER, Sierra Jones, US
|
| (73) |
Teva Pharmaceuticals International GmbH,
Schlüsselstrasse 12, 8645 Jona,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, skirti klasterinio galvos skausmo gydymui |
| ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE FOR TREATING CLUSTER HEADACHE |
| Payment date | Validity (years) | Amount | |
| 2018-10-22 | 13 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2019-04-21 |